<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Myelofibrosis PICOs 2-10</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            background-color: #f5f5f5;
            color: #333;
            padding: 20px;
            line-height: 1.6;
            max-width: 900px;
            margin: auto;
        }
        h1, h2 {
            color: #004080;
        }
        h1 {
            text-align: center;
        }
        ul {
            background: #fff;
            padding: 15px;
            border-radius: 10px;
            box-shadow: 2px 2px 10px rgba(0,0,0,0.1);
        }
        li {
            margin-bottom: 10px;
        }
        .section {
            background: #e6f7ff;
            padding: 15px;
            border-radius: 10px;
            margin-bottom: 20px;
        }
    </style>
</head>
<body>
    <h1>Myelofibrosis</h1>

<div class="section">
    <h2>Q2: <strong style="color:#004080;">Should interferon therapy be used in patients with early/prefibrotic Myelofibrosis?</strong></h2>
    <ol>
        <li><strong>Population:</strong> Patients with <strong style="color:#008000;">early/prefibrotic Myelofibrosis</strong></li>
        <li><strong>Intervention:</strong> <strong style="color:#800000;">Interferon therapy</strong></li>
        <li><strong>Comparator:</strong> <strong style="color:#FF0000;">No interferon therapy</strong></li>
        <li><strong>Outcomes:</strong>
            <ul>
                <li>Overall survival</li>
                <li>Progression to overt MF free survival</li>
                <li>Leukemia (blast phase transformation) free survival</li>
                <li>Molecular response</li>
                <li>Thrombosis risk</li>
                <li>Symptom response/QOL</li>
                <li>Adverse events</li>
            </ul>
        </li>
    </ol>
</div>

<div class="section">
    <h2>Q3: <strong style="color:#004080;">Should JAK inhibitor-naïve, higher-risk (DIPSS intermediate-2 and high) overt Myelofibrosis (primary and post-ET/PV MF) patients without symptomatic splenomegaly and/or inflammatory symptoms be treated with JAK inhibitors vs not?</strong></h2>
    <ol>
        <li><strong>Population:</strong> <strong style="color:#008000;">JAK inhibitor-naïve, higher-risk</strong> (DIPSS intermediate-2 and high risk) overt Myelofibrosis (primary and post-ET/PV MF) patients <strong style="color:#008000;">WITHOUT symptomatic splenomegaly and/or inflammatory symptoms</strong></li>
        <li><strong>Intervention:</strong> <strong style="color:#800000;">JAK inhibitors</strong>
            <ul>
                <li>Including: ruxolitinib, fedratinib, pacritinib, momelotinib</li>
            </ul>
        </li>
        <li><strong>Comparator:</strong> <strong style="color:#FF0000;">No JAK inhibitors</strong>
            <ul>
                <li>Comparators in studies will include placebo and best available therapy</li>
                <li style="background-color:#90EE90;">(examples of BAT include hydroxyurea, prednisone, danazol, EPO stimulating agents, thalidomide, lenalidomide)</li>
            </ul>
        </li>
        <li><strong>Outcomes:</strong>
            <ul>
                <li>Overall survival</li>
                <li>Leukemia (blast phase transformation) free survival</li>
                <li>Molecular response</li>
                <li>Hematological response</li>
                <li>Adverse effects</li>
                <li>QOL</li>
            </ul>
        </li>
    </ol>
</div>

<div class="section">
    <h2>Q4: <strong style="color:#004080;">Should JAK inhibitor-naïve, symptomatic lower-risk (DIPSS low, intermediate-1) overt Myelofibrosis (primary and post-ET/PV MF) patients be treated with JAK inhibitors vs not?</strong></h2>
    <ol>
        <li><strong>Population:</strong> <strong style="color:#008000;">JAK inhibitor-naïve, symptomatic lower-risk</strong> (DIPSS low, intermediate-1) overt Myelofibrosis (<em>overt primary and post-ET/PV MF</em>) patients
            <ul>
                <li>Excluding intermediate-2 or high-risk patients</li>
            </ul>
        </li>
        <li><strong>Intervention:</strong> <strong style="color:#800000;">JAK inhibitors</strong>
            <ul>
                <li>Ruxolitinib, Fedratinib, Pacritinib, Momelotinib</li>
            </ul>
        </li>
        <li><strong>Comparator:</strong> <strong style="color:#FF0000;">No JAK inhibitors</strong></li>
        <li><strong>Outcomes:</strong>
            <ul>
                <li>Overall survival</li>
                <li>Leukemia (blast phase transformation) free survival</li>
                <li>Spleen response/spleen volume reduction</li>
                <li>Symptom response: Quality of life/Symptom burden</li>
                <li>Molecular response</li>
                <li>Adverse events</li>
            </ul>
        </li>
    </ol>
</div>

<div class="section">
    <h2>Q5: <strong style="color:#004080;">Should JAK inhibitor-naïve, overt Myelofibrosis (primary, post-ET/PV) patients whose primary symptom burden is disease-related anemia be treated with anemia-directed therapy or JAK inhibitor therapy?</strong></h2>
    <ol>
        <li><strong>Population:</strong> <strong style="color:#008000;">JAK inhibitor-naïve, overt</strong> Myelofibrosis (primary, post-ET/PV) patients with disease-related anemia as the primary symptom
            <ul>
                <li style="background-color:#90EE90;">We are excluding early/prefibrotic MF here</li>
            </ul>
        </li>
        <li><strong>Intervention:</strong> <strong style="color:#800000;">Anemia-directed therapy</strong>
            <ul>
                <li>Best available therapy will include erythropoietin, darbepoetin, prednisone, danazol, thalidomide, lenalidomide</li>
            </ul>
        </li>
        <li><strong>Comparator:</strong> <strong style="color:#FF0000;">JAK inhibitor therapy</strong>
            <ul>
                <li>Pacritinib and Momelotinib</li>
                <li style="background-color:#90EE90;"><em>(These JAK inhibitors have potential to improve hemoglobin.)</em></li>
            </ul>
        </li>
        <li><strong>Outcomes:</strong>
            <ul>
                <li>Overall survival</li>
                <li>Leukemia (blast phase transformation) free survival</li>
                <li>Anemia response
                    <ol>
                        <li>Responses are defined in clinical trials, including rates of transfusion independence, clinical improvement in Hgb (>2g/dl in TI patients)</li>
                    </ol>
                </li>
                <li>Symptom burden reduction/QOL</li>
                <li>Adverse effects</li>
            </ul>
        </li>
    </ol>
</div>

<div class="section">
    <h2>Q6: <strong style="color:#004080;">Should patients with Myelofibrosis who experience JAK inhibitor-associated anemia be managed with second-line JAK inhibitors, compared to optimization strategies to maintain front-line therapy?</strong></h2>
    <ol>
        <li><strong>Population:</strong> Patients with <strong style="color:#008000;">overt Myelofibrosis</strong> (overt primary, post-ET/PVMF) experiencing <strong style="color:#008000;">JAK inhibitor-associated anemia</strong>
            <ul>
                <li style="background-color:#90EE90;">Will not include early/prefibrotic MF</li>
            </ul>
        </li>
        <li><strong>Intervention:</strong> <strong style="color:#800000;">Second-line JAK inhibitors</strong></li>
        <li><strong>Comparator:</strong> <strong style="color:#FF0000;">Optimization strategies</strong> to maintain front-line therapy</li>
        <li><strong>Outcomes:</strong>
            <ul>
                <li>Overall survival</li>
                <li>Leukemia (blast phase transformation) free survival</li>
                <li>Anemia response</li>
                <li>Spleen response</li>
                <li>Quality of life / Symptom burden</li>
                <li>Adverse effects</li>
            </ul>
        </li>
    </ol>
    <p style="background-color:#FFFF00; padding: 5px; border-radius: 5px;">
        <strong>Optimization strategies</strong> help manage anemia while maintaining the benefits of JAK inhibitor therapy, avoiding premature switching to second-line treatments. They can include <strong>dose modifications, addition of supportive medications, and transfusion support.</strong>
    </p>
</div>

<div class="section">
    <h2>Q7: <strong style="color:#004080;">Should patients with higher-risk Myelofibrosis (int-2, high) on first-line JAK inhibitor therapy be referred for early transplantation, compared to delayed transplantation after failure of response to JAK inhibitor therapy?</strong></h2>
    <ol>
        <li><strong>Population:</strong> Patients with <strong style="color:#008000;">higher-risk Myelofibrosis</strong> (DIPSS int-2, high) on <strong style="color:#008000;">first-line JAK inhibitor therapy</strong>
            <ul>
                <li style="background-color:#90EE90;">Focus on overt primary MF, also post-ET/post-PV MF</li>
                <li style="background-color:#90EE90;">Not early/prefibrotic MF</li>
            </ul>
        </li>
        <li><strong>Intervention:</strong> <strong style="color:#800000;">Early referral for transplantation</strong></li>
        <li><strong>Comparator:</strong> <strong style="color:#FF0000;">Delayed referral for transplantation</strong> after loss of response or disease progression on JAK inhibitor therapy</li>
        <li><strong>Outcomes:</strong>
            <ul>
                <li>Overall survival</li>
                <li>Transplant-related mortality</li>
                <li>Leukemia (blast phase transformation) free survival</li>
                <li>Relapse</li>
            </ul>
        </li>
    </ol>
</div>

<div class="section">
    <h2>Q8: <strong style="color:#004080;">Among JAK inhibitor-naïve patients scheduled for transplant, should JAK inhibitor therapy be initiated prior to transplantation?</strong></h2>
    <ol>
        <li><strong>Population:</strong> <strong style="color:#008000;">JAK inhibitor-naïve</strong> patients <strong style="color:#008000;">scheduled for transplantation</strong>
            <ul>
                <li><em>Overt primary and post-ET/PV patients with MF included here</em></li>
            </ul>
        </li>
        <li><strong>Intervention:</strong> <strong style="color:#800000;">Initiation of JAK inhibitor therapy</strong> prior to transplantation</li>
        <li><strong>Comparator:</strong> <strong style="color:#FF0000;">No initiation of JAK inhibitor therapy</strong> prior to transplantation</li>
        <li><strong>Outcomes:</strong>
            <ul>
                <li>Overall survival</li>
                <li>Transplant-related mortality</li>
                <li>Relapse</li>
                <li>Acute GVHD</li>
                <li>Chronic GVHD</li>
                <li>Time to engraftment/cumulative incidence of graft failure</li>
                <li>Infectious complications/viral reactivations</li>
            </ul>
        </li>
    </ol>
    <p style="background-color:#FFFF00; padding: 5px; border-radius: 5px;">
        <strong>Engraftment and graft failure</strong> are opposite outcomes in stem cell transplantation. <strong>Engraftment</strong> is the successful establishment of transplanted stem cells, leading to blood cell production and immune system recovery, typically within 2-4 weeks. <strong>Graft failure</strong> occurs when transplanted cells fail to engraft or are lost after initial engraftment, leading to poor blood cell production and potential need for re-transplantation. The outcome measure <strong>“Time to engraftment/cumulative incidence of graft failure”</strong> assesses both the speed of engraftment and the proportion of patients experiencing failure.
    </p>
</div>

<div class="section">
    <h2>Q9: <strong style="color:#004080;">Should aspirin therapy be used (or not) in all patients with Myelofibrosis?</strong></h2>
    <ol>
        <li><strong>Population:</strong> All patients with Myelofibrosis, including subgroups:
            <ul>
                <li>1) <strong style="color:#008000;">Prefibrotic</strong> 2) <strong style="color:#008000;">Overt</strong> (primary, post-ET/PV MF)</li>
                <li>2) <strong style="color:#008000;">JAK2 positive</strong> versus <strong style="color:#008000;">negative</strong></li>
            </ul>
        </li>
        <li><strong>Intervention:</strong> <strong style="color:#800000;">Aspirin therapy</strong></li>
        <li><strong>Comparator:</strong> <strong style="color:#FF0000;">No aspirin therapy</strong></li>
        <li><strong>Outcomes:</strong>
            <ul>
                <li>Arterial thrombosis
                    <ol>
                        <li>(CVA, TIA, ACS)</li>
                    </ol>
                </li>
                <li>Venous thrombosis
                    <ol>
                        <li>(DVT, PE, abdominal venous thrombosis, cerebral venous thrombosis)</li>
                    </ol>
                </li>
                <li>Bleeding complications
                    <ol>
                        <li>Clinically relevant non-major</li>
                        <li>Major</li>
                    </ol>
                </li>
                <li>Overall survival</li>
            </ul>
        </li>
    </ol>
</div>

<div class="section">
    <h2>Q10: <strong style="color:#004080;">Should overt Myelofibrosis patients with transfusional iron overload and elevated ferritin be treated with iron chelators or not?</strong></h2>
    <ol>
        <li><strong>Population:</strong> <strong style="color:#008000;">Overt Myelofibrosis</strong> patients with <strong style="color:#008000;">transfusional iron overload</strong> and elevated ferritin <strong>that will NOT be transplanted</strong>
            <ul>
                <li style="background-color:#90EE90;">Will include overt primary and post-ET/PV MF patients</li>
            </ul>
        </li>
        <li><strong>Intervention:</strong> <strong style="color:#800000;">Treatment with iron chelators</strong></li>
        <li><strong>Comparator:</strong> <strong style="color:#FF0000;">No treatment with iron chelators</strong></li>
        <li><strong>Outcomes:</strong>
            <ul>
                <li>Overall survival</li>
                <li>BP transformation/leukemia-free survival</li>
                <li>Cardiac complications (e.g., CHF, arrhythmia)</li>
                <li>Hepatic complications (e.g., cirrhosis, liver failure, hepatocellular carcinoma)</li>
                <li>Anemia response</li>
                <li>Adverse effects</li>
            </ul>
        </li>
    </ol>
    <p style="background-color:#FFFF00; padding: 5px; border-radius: 5px;">
        <strong>The main iron chelators used for transfusional iron overload include:</strong>
    </p>
    <ol style="background-color:#FFFF00; padding: 5px; border-radius: 5px;">
        <li>Deferasirox (Exjade, Jadenu)</li>
        <li>Deferoxamine (Desferal)</li>
        <li>Deferiprone (Ferriprox)</li>
    </ol>
</div>

</body>
</html>
